AcouSort AB (ACOU) AI Stock Analysis

AcouSort AB

(Nasdaq OMX AB:ACOU)

Select Model

Rating:46Neutral

Price Target:SEK 3.50▲(10.06% Upside)

Action:reiterated

Date:10/08/26

The score is held back primarily by heavy losses, negative gross profit, and ongoing negative free cash flow alongside shrinking equity. Technicals are largely neutral (no strong momentum signal), and valuation is constrained by a loss-making profile (negative P/E) with no dividend yield provided.

Positive Factors

Debt-free balance sheetNo reported debt materially lowers solvency and refinancing pressure, giving AcouSort greater flexibility while it develops and commercializes its acoustofluidic modules. This conservative financing profile can help preserve strategic options through the next several quarters despite current losses.

Negative Factors

Deeply negative profitabilityNegative gross profit and substantial operating and net losses show that AcouSort has not yet established a stable, scalable profit model. Persistent losses can limit internal reinvestment capacity and make future performance highly dependent on achieving meaningful margin improvement.

AcouSort AB (ACOU) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 68.15M
Dividend Yield: ―
Average Volume (3M): 32.69K
Price to Earnings (P/E): -6.2
Beta (1Y): 0.07
Revenue Growth: 43.22%
EPS Growth: 36.11%
Country: Sweden
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

AcouSort AB Business Overview & Revenue Model

Company Description

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular v...

How the Company Makes Money

AcouSort AB makes money primarily by commercializing its acoustofluidic separation technology to customers who need to integrate cell/particle separation and washing into their instruments or manufacturing workflows. Key revenue streams include: (1)...

AcouSort AB Financial Statement Overview

Summary

Revenue is growing (+7.6% TTM to 7.97m) and the company carries no debt, but the core financial picture is still weak: negative gross profit, large operating losses (EBIT -13.0m), net loss (-11.2m), and persistent cash burn (TTM FCF -6.9m). Equity has also fallen sharply (to ~9.8m), increasing future funding/dilution risk.

Income Statement

18Very Negative

Balance Sheet

63Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.97M	6.85M	4.74M	10.55M	4.96M	3.01M
Gross Profit	-7.90M	-14.50M	4.77M	8.39M	2.91M	548.00K
EBITDA	-12.17M	-14.33M	-15.89M	-16.70M	-12.86M	-11.46M
Net Income	-11.22M	-12.15M	-15.08M	-17.09M	-13.21M	-12.38M
Balance Sheet
Total Assets	21.47M	17.89M	12.32M	34.51M	42.66M	36.56M
Cash, Cash Equivalents and Short-Term Investments	9.48M	6.29M	3.57M	23.99M	33.97M	31.52M
Total Debt	0	0	0	0	0	0
Total Liabilities	11.67M	1.59M	3.86M	10.38M	22.54M	3.54M
Stockholders Equity	9.81M	16.30M	8.46M	24.14M	20.11M	33.02M
Cash Flow
Free Cash Flow	-6.91M	-17.27M	-19.84M	-31.77M	2.95M	-12.23M
Operating Cash Flow	-6.58M	-16.78M	-18.81M	-31.56M	3.96M	-10.92M
Investing Cash Flow	-1.39M	-488.00K	-1.02M	-1.16M	-1.01M	-1.31M
Financing Cash Flow	-118.00K	18.98M	-157.00K	22.08M	0	35.63M

AcouSort AB Technical Analysis

Technical Analysis SentimentNeutral

Last Price3.18

Price Trends

50DMA3.02Positive

100DMA3.34Negative

200DMA3.31Negative

Market Momentum

MACD0.07Positive

RSI51.27Neutral

STOCH37.19Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Neutral. The current price of 3.18 is below the 20-day moving average (MA) of 3.23, above the 50-day MA of 3.02, and below the 200-day MA of 3.31, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 51.27 is Neutral, neither overbought nor oversold. The STOCH value of 37.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACOU.

AcouSort AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:ACOU against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CEVI	83Outperform	SEK 4.67B	33.84	15.23%	1.41%	1.95%	-8.91%
SE:FLUI	55Neutral	SEK 38.33M	13.65	21.37%	―	837.37%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:BICO	48Neutral	SEK 1.73B	-2.06	-49.84%	―	-15.45%	-164.23%
SE:ACOU	46Neutral	SEK 68.15M	-6.19	-76.74%	―	43.22%	36.11%
SE:IMMNOV	45Neutral	SEK 33.70M	-0.30	-279.07%	―	31.66%	79.68%
SE:QLINEA	43Neutral	SEK 282.34M	-1.13	-48.10%	―	33.26%	90.73%

* Healthcare Sector Average

Performance Comparison

SE:ACOU and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:ACOU	AcouSort AB	3.22	0.35	12.20%
SE:BICO	BICO Group AB Class B	24.45	3.45	16.43%
SE:CEVI	CellaVision AB	195.60	17.76	9.98%
SE:IMMNOV	Immunovia AB	0.05	-0.27	-84.28%
SE:QLINEA	Q-linea AB	14.90	-10.30	-40.87%
SE:FLUI	Fluicell AB	27.90	14.90	114.62%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026

AcouSort AB AI Stock Analysis